arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Inmune Bio, Inc.

INMB

$2.08 ▲ +0.18 (+9.19%) at close

10 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Inmune Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $51.5M

Dividend Yield —

Revenue Growth 257.1% ↗

Op. Margin —

ROIC -159.1% ↘

FCF / Share $-0.95 ↗

Trailing P/E —

Price / Book 2.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$50.00K

↑ +257.1% —

Net Income Profit after all expenses

$-45.93M

↓ -9.2% —

FCF / Share Free cash flow per share

$-0.95

↑ +43.0% —

Long-Term Debt Long-term obligations

$15.00M

— 0.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue Growth YoY (%)	257.1% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3114%)	-91.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1237%)	-58.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-832%)	106.6% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1233%)	1545.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+19218%)	—	—	—	—	—
EPS Growth YoY (%)	11.8% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-26.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-9.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	19.1% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-9.2% Weak ↑ Weak Improving Year-over-year change in net income	-40.2% Weak ↑ Weak Improving Year-over-year change in net income	-9.9% Weak ↑ Weak Improving Year-over-year change in net income	10.0% Fair ↑ Fair Improving Year-over-year change in net income	-150.8% Weak ↑ Weak Improving Year-over-year change in net income	-57.6% Weak ↑ Weak Improving Year-over-year change in net income	38.3% Excellent Excellent Year-over-year change in net income	-1396.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	43.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-151.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	47.3% Excellent Excellent Year-over-year change in free cash flow	28.4% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—
Revenue CAGR 3Y (%)	-48.9% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-57.4% Weak Weak Compound annual revenue growth over 3 years	141.5% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—
Revenue CAGR 5Y (%)	35.4% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
FCF / Net Income (x)	0.51x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.40x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.17x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	-159.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-71.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-62.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-27.3% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-28.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-24.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-26.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-59.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-4.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-146.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-107.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-52.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-31.7% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-29.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-30.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-31.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-71.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-5.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-195.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1402%)	-131.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-974%)	-80.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-636%)	-45.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-403%)	-37.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-352%)	-31.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-308%)	-32.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-317%)	-75.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-601%)	-4.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-131%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Debt to Equity (x)	—	0.47x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-22%)	—	0.25x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-58%)	—	—	—	—	—	—
Interest Coverage (x)	—	-54.04x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-13.06x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-12.89x Weak Weak Operating income divided by interest expense Optimal: > 5x	-29.60x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—
Net Debt (USD)	$-24.75M	$-5.92M	$-35.85M	$-37.15M	$-74.81M	$-21.97M	$-7.00M	$-186.20K	$-1.37M	$-141.66K
Debt / EBITDA (x)	—	-0.35x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	-0.58x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.01	$0.02	$0.01	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.86	$-2.11	$-1.67	$-1.52	$-1.88	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.95	$-1.67	$-0.67	$-1.27	$-1.77	—	—	—	—	—
Book Value per Share (USD)	$0.88	$1.44	$2.08	$3.35	$4.50	$2.87	$2.19	$1.90	$2.18	—
Tangible Book Value per Share (USD)	$0.88	$0.70	$1.16	$2.43	$3.57	$1.65	$0.66	$0.00	$0.19	—
Basic Weighted Avg Shares (shares)	24.76M	19.94M	17.98M	17.93M	16.13M	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$21.47M	$15.44M	$21.48M	$53.76M	$78.25M	$22.21M	$7.06M	—	—	—
LT Debt (USD)	—	$15.00M	—	$15.00M	—	—	—	—	—	—
Total Equity (USD)	$23.52M	$32.10M	$37.34M	$60.10M	$80.22M	$38.75M	$23.61M	$16.54M	$18.10M	$-149.20K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Sales/Revenue/Turnover (USD)	$50.00K	$14.00K	$155.00K	$374.00K	$181.00K	$11.00K	—	$0.00	$0.00	—
Depreciation Expense (USD)	$84.00K	—	—	—	—	—	—	—	—	—
Net Income, GAAP (USD)	$-45.93M	$-42.08M	$-30.01M	$-27.30M	$-30.34M	$-12.10M	$-7.68M	$-12.44M	$-831.49K	—
Operating Cash Flow (USD)	$-22.58M	$-33.36M	$-11.98M	$-22.69M	$-28.50M	$-8.94M	$-5.38M	$-2.06M	$-761.83K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 35 quarters

Inmune Bio, Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare INMB with peers